Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00299195 · ClinicalTrials.gov registry record · NA
A Randomized Study of Sulindac in Oral Premalignant Lesions
A NA study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- NA
- Development phase
- 63
- Enrollment target
NCT00299195: Completed NA study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT00299195 is a NA study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 63 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00299195, a NA study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 63 participants
- Enrollment target
Study Summary
The purpose of this study is to see if a drug called sulindac can prevent the development of changes in the mouth that are related to oral pre-cancer growths (oral epithelial dysplasia) or oral cancer. Sulindac is an anti-inflammatory drug that has already been tested in people with arthritis (inflammation of a joint). This study is being done by Memorial Sloan-Kettering Cancer Center in New York, Amrita Institute of Medical Sciences and Research Center in Cochin, India, and Regional Cancer Centre (RCC) in Trivandrum, India.
Interventions
- DRUG Placebo
- DRUG sulindac
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2006-02-23 |
| Est. Completion | 2020-01-06 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00299195
The ClinicalTrials.gov registry entry for NCT00299195 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 63 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00299195 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00299195 about?
NCT00299195 is a clinical study titled "A Randomized Study of Sulindac in Oral Premalignant Lesions". The purpose of this study is to see if a drug called sulindac can prevent the development of changes in the mouth that are related to oral pre-cancer growths (oral epithelial dysplasia) or oral cancer. Sulindac is an anti-inflammatory drug that has already been tested in people with arthritis (infla...
What is the current status of trial NCT00299195?
This trial is currently completed. It is a NA study. The enrollment target is 63 participants. The study started on 2006-02-23. Estimated completion is 2020-01-06.
What interventions are being tested in trial NCT00299195?
The interventions under investigation include: Placebo (DRUG), sulindac (DRUG).
Who is sponsoring clinical trial NCT00299195?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.